Why can’t I order GLP-1 products via the website?

Due to online platform restrictions, GLP-1 compounds cannot be purchased directly through our standard website checkout. All GLP-1 orders are therefore processed manually via WhatsApp, with secure payment arranged through Open Banking. Once confirmed, UK orders are dispatched via Royal Mail Tracked 24, providing a fast and fully tracked delivery service.

Cagrilintide Price UK

Our current Cagrilintide research range:

Cagrilintide 10mg — £85

To order or check current availability, contact Axiom Labs UK via WhatsApp.

Prices and availability may change.

What Is Cagrilintide?

Cagrilintide is an investigational, long-acting amylin analogue being studied within metabolic and body-weight regulation research.

Unlike Semaglutide, Tirzepatide and Retatrutide, Cagrilintide does not primarily act through the GLP-1 receptor.

Instead, it has been developed to mimic and extend signalling associated with amylin, a naturally occurring pancreatic hormone involved in appetite, satiety and food-intake regulation.

Its different mechanism has generated considerable scientific interest both as an independent research compound and in research examining amylin and GLP-1 pathways together.

How Does Cagrilintide Work?

Cagrilintide is designed as a long-acting analogue of amylin.

Amylin is naturally co-secreted with insulin by pancreatic beta cells following food intake and contributes to physiological signalling associated with nutrient intake and satiety.

Research into amylin signalling has examined its involvement in:

• Appetite regulation

• Satiety signalling

• Food-intake regulation

• Gastric emptying

• Energy balance

• Metabolic regulation

• Body-weight regulation

Cagrilintide's extended activity allows researchers to investigate this pathway using a long-acting compound.

Is Cagrilintide a GLP-1?

No. Cagrilintide is not a GLP-1 receptor agonist.

This is an important distinction.

Cagrilintide is a long-acting amylin analogue, whereas compounds such as Semaglutide act through GLP-1 receptors.

It is frequently discussed alongside GLP-1 compounds because both pathways are being investigated within modern metabolic and appetite-regulation research.

The different mechanisms have also created significant interest in research examining combined amylin and GLP-1 receptor signalling.

What Is Amylin?

Amylin is a peptide hormone naturally produced by pancreatic beta cells and released alongside insulin in response to nutrient intake.

It contributes to signalling between the gastrointestinal system, pancreas and central nervous system.

Scientific research has investigated amylin's involvement in:

• Satiety

• Meal-related signalling

• Food intake

• Gastric emptying

• Glucose regulation

• Energy balance

The amylin pathway therefore represents a different approach to metabolic research compared with incretin pathways such as GLP-1 and GIP.

Cagrilintide Research

Cagrilintide has been investigated in clinical research examining obesity and body-weight regulation.

Research has examined areas including:

• Body-weight changes

• Appetite

• Satiety

• Food intake

• Waist circumference

• Metabolic markers

• Safety

• Tolerability

Scientific interest has also increasingly focused on combining Cagrilintide with compounds targeting other metabolic pathways.

This has made Cagrilintide particularly relevant to research into multi-pathway approaches to metabolic regulation.

Cagrilintide and GLP-1 Research

One of the most interesting areas of Cagrilintide research involves combining amylin signalling with GLP-1 receptor signalling.

These pathways influence metabolic regulation through different biological mechanisms.

Rather than increasing the number of receptors targeted by a single molecule, researchers can investigate what occurs when two separate metabolic pathways are activated alongside one another.

This has contributed to considerable research interest surrounding combinations of Cagrilintide and GLP-1 receptor agonists.

Cagrilintide and Semaglutide Research

Cagrilintide and Semaglutide have different mechanisms.

Cagrilintide:
Long-acting amylin analogue

Semaglutide:
GLP-1 receptor agonist

The combination of Cagrilintide and Semaglutide has been investigated clinically as CagriSema.

This research approach allows scientists to investigate simultaneous amylin and GLP-1 receptor pathways rather than relying on either mechanism independently.

Cagrilintide vs Semaglutide

Although both compounds are associated with metabolic research, they work through different pathways.

Cagrilintide — Amylin analogue

Semaglutide — GLP-1 receptor agonist

Semaglutide primarily activates GLP-1 receptors, whereas Cagrilintide is designed around amylin receptor signalling.

This makes the compounds mechanistically distinct.

Cagrilintide vs Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist.

Cagrilintide is a long-acting amylin analogue.

Therefore:

Cagrilintide — Amylin pathway

Tirzepatide — GLP-1 + GIP pathways

Both are relevant to modern metabolic research but investigate substantially different biological mechanisms.

Cagrilintide vs Retatrutide

Retatrutide is an investigational triple-receptor agonist targeting:

GLP-1 + GIP + Glucagon

Cagrilintide instead acts as a long-acting amylin analogue.

The compounds therefore represent two different approaches to next-generation metabolic research: multi-receptor incretin/glucagon agonism and amylin-based signalling.

Current Cagrilintide Research Status

Cagrilintide remains an investigational compound undergoing clinical research.

Research continues to investigate its potential effects independently and when combined with other metabolic pathways.

The compound has attracted particular scientific interest due to its mechanism being distinct from GLP-1, GIP and glucagon receptor agonists.

Frequently Asked Questions About Cagrilintide

What is Cagrilintide?

Cagrilintide is an investigational long-acting amylin analogue being studied within metabolic and body-weight regulation research.

Is Cagrilintide a GLP-1?

No. Cagrilintide is not a GLP-1 receptor agonist. It is an amylin analogue.

What does Cagrilintide target?

Cagrilintide is designed around the amylin signalling pathway, which is involved in physiological processes including satiety and food-intake regulation.

What is CagriSema?

CagriSema is the name used in clinical development for the combination of Cagrilintide and Semaglutide, bringing together amylin and GLP-1 receptor pathways.

How is Cagrilintide different from Semaglutide?

Cagrilintide is an amylin analogue, while Semaglutide is a GLP-1 receptor agonist.

How is Cagrilintide different from Retatrutide?

Cagrilintide uses an amylin-based mechanism. Retatrutide targets GLP-1, GIP and glucagon receptors.

What strength of Cagrilintide does Axiom Labs UK stock?

Our current research range includes:

Cagrilintide 10mg — £85

For current stock availability, please contact Axiom Labs UK directly via WhatsApp.

Cagrilintide Research UK – Axiom Labs

Axiom Labs UK supplies Cagrilintide 10mg for legitimate laboratory, analytical and scientific research applications.

Due to online platform restrictions, Cagrilintide orders are handled exclusively via WhatsApp and cannot be completed through our standard online checkout.

Cagrilintide 10mg — £85

For current availability and research procurement enquiries, please contact Axiom Labs UK via WhatsApp.

Important Research Notice

Cagrilintide remains an investigational research compound.

Research compounds supplied by Axiom Labs UK are intended strictly for legitimate laboratory, analytical and scientific research purposes.

They are not supplied as medicines and are not intended for human consumption or self-administration.

Information provided on this page is for educational and scientific reference purposes only and does not constitute medical advice.